Remove tag prime-therapeutics
article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Gene therapies for rare inherited diseases are very expensive, as they tend to be the only therapeutic option available to patients and are often curative.

article thumbnail

Scientists turn cancer cells into anticancer agents

Drug Discovery World

Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” . The researchers also built a two-layered safety switch into the cancer cell, which can eradicate the therapeutic tumour cells if needed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

XTalks

This is not a debate on approval,” said Stacie Weninger, PhD, president of the F-Prime Biomedical Research Initiative, in a focused topic session on the impact of drug approval on future clinical trials held on Tuesday July 27. With a $56,000 price tag for a year’s worth of treatment, Aduhelm is far from the most expensive drug on the market.

article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

In this way, the platform allows for the generation of a vast number of therapeutic molecules from a very well formatted platform, which is the core strength of the technology. For their second molecule, the peptide was swapped out with a Wilm’s tumor 1 (WT1) peptide, and the third one has a KRAS peptide.

Protein 98
article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Stefan Ewert, PhD, Associate Director, Biologics Center, Novartis Institutes for Biomedical Research, on: ‘Computational counterselection identifies nonspecific therapeutic biologic candidates’. The panel discussion will be hosted by chairperson Erasmus and Greiff on the current state of AI in antibody therapeutics.

Protein 59